Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 29th July 2020
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Boehringer Ingelheim acquires Global Stem Cell Technology
Jan Spaas, CEO of GST.
Acquisition follows two years of successful partnership. 

Boehringer Ingelheim has acquired Global Stem Cell Technology (GST), a Belgian biotech firm that develops stem cell products for dogs and horses.

The acquisition follows Boehringer Ingelheim's partnership with GST in 2018. In 2019, the companies launched Arti-Cell® Forte in Europe, the first-ever stem cell product in the veterinary sphere granted marketing authorisation by the European Commission.

In a press release, Boehringer Ingelheim states that the acquisition and integration of GST will accelerate the development pipeline of Boehringer Ingelheim while maintaining its focus on setting new standards of care for animals.

Jean-Luc Michel, Head of Global Strategic Marketing, Boehringer Ingelheim Animal Health, commented: "Collaboration with external partners plays an essential role in helping us expand our portfolio. After two years of a very successful partnership, we have decided to acquire GST. We are convinced that its expertise in the field of state-of-the-art stem cell products will help us bring even more innovative solutions to our customers."

Jan Spaas, CEO of GST added: “Boehringer Ingelheim wants to lead a new wave of innovation in the veterinary field. This ambition is a natural fit with GST’s management, staff and vision. From the very beginning, we aimed to change the veterinary field, a role we will continue to play as a new R&D division within Boehringer Ingelheim,”

The financial terms of the deal have not been disclosed. 

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
BSAVA publishes fifth Manual of Canine and Feline Neurology

The BSAVA has published the fifth edition of its BSAVA Manual of Canine and Feline Neurology.

The new edition has been reviewed and updated, including new developments in diagnostics, therapeutic approaches and clinical decision-making. It is structured to support clinicians through diagnosis, treatment and long-term management.

The guide features five new chapters covering acute myelopathies, chronic myelopathies, emergency protocols, neurotoxicology and neuro-oncology.

It also includes over 100 videos, including demonstrations of neurological examinations, clinical presentations and diagnostic procedures.

Nicola Lloyd, publishing manager, said: "Whether you're a general practitioner seeking practical guidance, or a specialist aiming to refine your expertise, this edition remains an indispensable reference for anyone involved in the care of neurologically compromised dogs and cats."